GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Insmed Inc (NAS:INSM) » Definitions » Piotroski F-Score

Insmed (Insmed) Piotroski F-Score : 3 (As of May. 11, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Insmed Piotroski F-Score?

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Insmed has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Insmed's Piotroski F-Score or its related term are showing as below:

INSM' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 3   Max: 5
Current: 3

During the past 13 years, the highest Piotroski F-Score of Insmed was 5. The lowest was 2. And the median was 3.


Insmed Piotroski F-Score Historical Data

The historical data trend for Insmed's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insmed Piotroski F-Score Chart

Insmed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5.00 3.00 4.00 4.00 3.00

Insmed Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.00 3.00 3.00 4.00 3.00

Competitive Comparison of Insmed's Piotroski F-Score

For the Biotechnology subindustry, Insmed's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Insmed's Piotroski F-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Insmed's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Net Income was -159.764 + -244.809 + -158.933 + -186.061 = $-749.6 Mil.
Cash Flow from Operations was -146.303 + -122.792 + -136.333 + -130.819 = $-536.2 Mil.
Revenue was 65.214 + 77.229 + 79.072 + 83.693 = $305.2 Mil.
Gross Profit was 51.384 + 60.635 + 62.366 + 65.25 = $239.6 Mil.
Average Total Assets from the begining of this year (Dec22)
to the end of this year (Dec23) was
(1656.435 + 1517.717 + 1439.139 + 1324.873 + 1329.837) / 5 = $1453.6002 Mil.
Total Assets at the begining of this year (Dec22) was $1,656.4 Mil.
Long-Term Debt & Capital Lease Obligation was $1,193.4 Mil.
Total Current Assets was $929.1 Mil.
Total Current Liabilities was $225.6 Mil.
Net Income was -94.621 + -95.645 + -131.145 + -160.123 = $-481.5 Mil.

Revenue was 53.107 + 65.221 + 67.73 + 59.3 = $245.4 Mil.
Gross Profit was 40.916 + 48.826 + 54.259 + 46.231 = $190.2 Mil.
Average Total Assets from the begining of last year (Dec21)
to the end of last year (Dec22) was
(1243.508 + 1153.315 + 1053.354 + 994.817 + 1656.435) / 5 = $1220.2858 Mil.
Total Assets at the begining of last year (Dec21) was $1,243.5 Mil.
Long-Term Debt & Capital Lease Obligation was $1,169.7 Mil.
Total Current Assets was $1,273.4 Mil.
Total Current Liabilities was $190.2 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Insmed's current Net Income (TTM) was -749.6. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Insmed's current Cash Flow from Operations (TTM) was -536.2. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec22)
=-749.567/1656.435
=-0.45251821

ROA (Last Year)=Net Income/Total Assets (Dec21)
=-481.534/1243.508
=-0.38723836

Insmed's return on assets of this year was -0.45251821. Insmed's return on assets of last year was -0.38723836. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Insmed's current Net Income (TTM) was -749.6. Insmed's current Cash Flow from Operations (TTM) was -536.2. ==> -536.2 > -749.6 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec22 to Dec23
=1193.352/1453.6002
=0.82096301

Gearing (Last Year: Dec22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec21 to Dec22
=1169.739/1220.2858
=0.9585779

Insmed's gearing of this year was 0.82096301. Insmed's gearing of last year was 0.9585779. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec23)=Total Current Assets/Total Current Liabilities
=929.063/225.629
=4.11765775

Current Ratio (Last Year: Dec22)=Total Current Assets/Total Current Liabilities
=1273.383/190.243
=6.69345521

Insmed's current ratio of this year was 4.11765775. Insmed's current ratio of last year was 6.69345521. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Insmed's number of shares in issue this year was 144.852. Insmed's number of shares in issue last year was 132.8. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=239.635/305.208
=0.78515308

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=190.232/245.358
=0.77532422

Insmed's gross margin of this year was 0.78515308. Insmed's gross margin of last year was 0.77532422. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec22)
=305.208/1656.435
=0.18425595

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec21)
=245.358/1243.508
=0.19731116

Insmed's asset turnover of this year was 0.18425595. Insmed's asset turnover of last year was 0.19731116. ==> Last year's asset turnover is higher ==> Score 0.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+0
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Insmed has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Insmed  (NAS:INSM) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Insmed Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Insmed's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Insmed (Insmed) Business Description

Traded in Other Exchanges
Address
700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a global biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the US for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The company's earlier-stage clinical pipeline includes Brensocatib, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for pulmonary arterial hypertension.
Executives
Flammer Martina M.d. officer: Chief Medical Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Roger Adsett officer: Chief Commercial Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
John Drayton Wise officer: Chief Commercial Officer 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
Michael Alexander Smith officer: General Counsel, Senior VP 700 US HIGHWAY 202/206, BRIDGEWATER NJ 08807
William Lewis officer: President & CEO 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Schaeffer Orlov S Nicole officer: Chief People Strategy Officer INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Sara Bonstein officer: Chief Financial Officer 305 COLLEGE ROAD EAST, PRINCETON NJ 08540
Melvin Md Sharoky director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Leo Lee director 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
David R Brennan director C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Steinar J Engelsen director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
John Soriano officer: Chief Compliance Officer 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Christine A Pellizzari officer: General Counsel & Secretary 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Elizabeth M Anderson director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807